
Intellia Therapeutics, Inc. – NASDAQ:NTLA
Intellia Therapeutics stock price today
Intellia Therapeutics stock price monthly change
Intellia Therapeutics stock price quarterly change
Intellia Therapeutics stock price yearly change
Intellia Therapeutics key metrics
Market Cap | 1.22B |
Enterprise value | 2.47B |
P/E | -5.57 |
EV/Sales | 47.48 |
EV/EBITDA | -5.40 |
Price/Sales | 55.02 |
Price/Book | 2.32 |
PEG ratio | 0.08 |
EPS | -5.35 |
Revenue | 52.60M |
EBITDA | -512.35M |
Income | -485.50M |
Revenue Q/Q | 129.53% |
Revenue Y/Y | -1.62% |
Profit margin | -909.78% |
Oper. margin | -879.04% |
Gross margin | 0% |
EBIT margin | -879.04% |
EBITDA margin | -973.99% |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeIntellia Therapeutics stock price history
Intellia Therapeutics stock forecast
Intellia Therapeutics financial statements
$39
Potential upside: 280.48%
Analysts Price target
Financials & Ratios estimates
Jun 2023 | 13.59M | -123.68M | -909.82% |
---|---|---|---|
Sep 2023 | 11.99M | -122.22M | -1019.21% |
Dec 2023 | -1.91M | -132.16M | 6894.16% |
Mar 2024 | 28.93M | -107.43M | -371.3% |
Jun 2023 | 1323240000 | 218.35M | 16.5% |
---|---|---|---|
Sep 2023 | 1243349000 | 205.93M | 16.56% |
Dec 2023 | 1300977000 | 250.80M | 19.28% |
Mar 2024 | 1259589000 | 223.45M | 17.74% |
Jun 2023 | -90.32M | -34.53M | 2.51M |
---|---|---|---|
Sep 2023 | -101.38M | 79.5M | 19.10M |
Dec 2023 | -93.05M | 45.93M | 106.48M |
Mar 2024 | -120.66M | 5.90M | 59.99M |
Intellia Therapeutics alternative data
Sep 2023 | 598 |
---|---|
Oct 2023 | 598 |
Nov 2023 | 598 |
Dec 2023 | 598 |
Jan 2024 | 598 |
Feb 2024 | 598 |
Mar 2024 | 526 |
Apr 2024 | 526 |
May 2024 | 526 |
Jun 2024 | 526 |
Jul 2024 | 526 |
Intellia Therapeutics other data
Period | Buy | Sel |
---|---|---|
Jun 2023 | 0 | 5000 |
Jul 2023 | 0 | 2492 |
Oct 2023 | 0 | 265 |
Jan 2024 | 0 | 50528 |
Mar 2024 | 0 | 2902 |
Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
---|---|---|---|---|---|---|---|
Sale | BASTA JAMES officer: EVP, General Counsel | Common Stock | 2,297 | $32.99 | $75,778 | ||
Sale | CLARK ELIANA officer: EVP, Chief Technical O.. | Common Stock | 605 | $32.99 | $19,959 | ||
Sale | SEPP-LORENZINO LAURA officer: EVP, Chi.. | Common Stock | 1,608 | $28.66 | $46,085 | ||
Sale | SEPP-LORENZINO LAURA officer: EVP, Chi.. | Common Stock | 1,608 | $28.66 | $46,085 | ||
Sale | SEPP-LORENZINO LAURA officer: EVP, Chi.. | Common Stock | 667 | $29.38 | $19,596 | ||
Sale | SEPP-LORENZINO LAURA officer: EVP, Chi.. | Common Stock | 667 | $29.38 | $19,596 | ||
Sale | HICKS DEREK officer: EVP, Chief Business Of.. | Common Stock | 3,877 | $29.46 | $114,216 | ||
Sale | BASTA JAMES officer: EVP, General Counsel | Common Stock | 3,805 | $29.46 | $112,095 | ||
Sale | CLARK ELIANA officer: EVP, Chief Technical O.. | Common Stock | 307 | $30.12 | $9,247 | ||
Sale | CLARK ELIANA officer: EVP, Chief Technical O.. | Common Stock | 4,301 | $29.46 | $126,707 |
Quarter | Transcript |
---|---|
Q1 2024 9 May 2024 | Q1 2024 Earnings Call Transcript |
Q4 2023 22 Feb 2024 | Q4 2023 Earnings Call Transcript |
Q3 2023 9 Nov 2023 | Q3 2023 Earnings Call Transcript |
Q2 2023 3 Aug 2023 | Q2 2023 Earnings Call Transcript |
Insider | Compensation |
---|---|
Dr. John M. Leonard (1957) Pres, Chief Executive Officer & Director | $912,790 |
Dr. Laura Sepp-Lorenzino (1961) Executive Vice President & Chief Scientific Officer | $609,380 |
Mr. Glenn G. Goddard (1971) Executive Vice President, Chief Financial Officer & Treasurer | $562,450 |
With Intellia Therapeutics, Human Patience Beat Hot-Take Trading: Still At 'Buy'
I Missed The Quantum Rally - I Won't Miss The Next One
CRISPR Therapeutics And Intellia Therapeutics: Balancing Market Uncertainty Against Pipeline Catalysts
Undercovered Dozen: Virgin Galactic, Gold Fields, Matador Resources, EHang +
Editas And Intellia: Strategic Shifts And Long-Term Investment Potential
CRISPR Therapeutics: Unfairly Punished By The Issues Of Its Peers
Intellia Therapeutics Disappointed Investors Again On January 9 (Rating Downgrade)
Intellia Therapeutics: Buying The Path To Commercialization
3 Biotech Stocks For The Second Half Of 2024
-
What's the price of Intellia Therapeutics stock today?
One share of Intellia Therapeutics stock can currently be purchased for approximately $10.25.
-
When is Intellia Therapeutics's next earnings date?
Unfortunately, Intellia Therapeutics's (NTLA) next earnings date is currently unknown.
-
Does Intellia Therapeutics pay dividends?
No, Intellia Therapeutics does not pay dividends.
-
How much money does Intellia Therapeutics make?
Intellia Therapeutics has a market capitalization of 1.22B and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 30.4% to 36.28M US dollars.
-
What is Intellia Therapeutics's stock symbol?
Intellia Therapeutics, Inc. is traded on the NASDAQ under the ticker symbol "NTLA".
-
What is Intellia Therapeutics's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Intellia Therapeutics?
Shares of Intellia Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Intellia Therapeutics's key executives?
Intellia Therapeutics's management team includes the following people:
- Dr. John M. Leonard Pres, Chief Executive Officer & Director(age: 68, pay: $912,790)
- Dr. Laura Sepp-Lorenzino Executive Vice President & Chief Scientific Officer(age: 64, pay: $609,380)
- Mr. Glenn G. Goddard Executive Vice President, Chief Financial Officer & Treasurer(age: 54, pay: $562,450)
-
How many employees does Intellia Therapeutics have?
As Jul 2024, Intellia Therapeutics employs 526 workers.
-
When Intellia Therapeutics went public?
Intellia Therapeutics, Inc. is publicly traded company for more then 9 years since IPO on 6 May 2016.
-
What is Intellia Therapeutics's official website?
The official website for Intellia Therapeutics is intelliatx.com.
-
Where are Intellia Therapeutics's headquarters?
Intellia Therapeutics is headquartered at 40 Erie Street, Cambridge, MA.
-
How can i contact Intellia Therapeutics?
Intellia Therapeutics's mailing address is 40 Erie Street, Cambridge, MA and company can be reached via phone at 857 285 6200.
-
What is Intellia Therapeutics stock forecast & price target?
Based on 2 Wall Street analysts` predicted price targets for Intellia Therapeutics in the last 12 months, the avarage price target is $39. The average price target represents a 280.48% change from the last price of $10.25.
Intellia Therapeutics company profile:

Intellia Therapeutics, Inc.
intelliatx.comNASDAQ
526
Biotechnology
Healthcare
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemophilia A and hemophilia B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo pipeline includes NTLA-5001 for the treatment of acute myeloid leukemia; and proprietary programs focused on developing engineered cell therapies to treat various oncological and autoimmune disorders. In addition, it offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. Intellia Therapeutics, Inc. has license and collaboration agreements with Novartis Institutes for BioMedical Research, Inc. to engineer hematopoietic stem cells for the treatment of sickle cell disease; Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; Ospedale San Raffaele; and a strategic collaboration with SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases. The company was formerly known as AZRN, Inc. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Cambridge, MA 02139
CIK: 0001652130
ISIN: US45826J1051
CUSIP: 45826J105